miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The Most Active Startup Acquirers Of The Past 3 Years Aren’t Always Who You’d Expect

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: The Most Active Startup Acquirers Of The Past 3 Years Aren’t Always Who You’d Expect Date: 2026-03-20 11:00 Source: https://news.crunchbase.com/ma/most-active-startup-acquirers-3-years-crm-openai-snowflake/ <p>Companies that buy a lot of startups don’t always have a lot in common.</p…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Snowflake has 19 acquisitions to date

    60% confidence

  • Salesforce, OpenAI and Snowflake are the most prolific acquirers of seed- and venture-backed startups in recent years

    60% confidence

  • Six companies made six or more known purchases in the past three years

    60% confidence

  • The AI sector's appetite for acqui-hires and smaller purchases of earlier-stage startups continues to boost momentum

    60% confidence

  • The pace of startup M&A dealmaking remains fairly robust in 2026

    60% confidence

  • Salesforce has purchased at least 91 companies in the past 20 years

    60% confidence

  • OpenAI has bought 16 companies in the past three years

    60% confidence

  • 79 companies acquired three or more seed- or venture-backed startups in the past three years

    60% confidence

Data points we hold from this source

Salesforce · total acquisitions91 companies
OpenAI · total acquisitions16 companies
Snowflake Inc. · total acquisitions19 companies
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
The Most Active Startup Acquirers Of The Past 3 Years Aren’t Always Who You’d Expect — Source | Via News | es.VIA.NEWS